Longeveron Inc.
LGVNNasdaq
$0.62
↑ +1.4%Jul 17 close · end-of-day
Price
1Y↓ -57.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.4B
Enterprise Value
$15.4B
P/E
—
P/S
12678.5
P/B
961.9
EV/EBITDA
—
PEG
—
FCF Yield
-0.1%
Dividend Yield
—
Revenue (TTM)
$1.2M
Net Income (TTM)
-$22.4M
Free Cash Flow (TTM)
-$18.5M
Gross Margin
65.1%
Operating Margin
-1881.7%
Net Margin
-1844.5%
ROE
-139.9%
ROIC
-6719.7%
Debt / Equity
—
Net Cash
$15.8M
Return 1Y
-59.6%
Company profile
Longeveron Inc. develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product. It is conducting Phase 1 and 2 clinical trials in various indications.
- CEO
- K. Chris Min
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Florida
- Website
- longeveron.com
Management & directors
- Hare JoshuaChief Scientific Officer
- Agafonova NataliyaChief Medical Officer
- Blass DevinCTO & SVP of CMC
- Lehr Paul TGeneral Counsel, Secretary
- Locklear LisaChief Financial Officer
- Willard Stephen HChief Executive Officer
- Powell James NathanielChief Executive Officer
- Hashad Mohamed Wa'El AhmedChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
LGVN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$398,000.00↑ +4.5%
Diluted EPS-$0.19↓ -44.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.6M | $1.3M | $1.2M | $709,000.00 | $2.4M | $1.2M |
| Gross profit | $1.8M | $590,000.00 | $497,000.00 | $221,000.00 | $1.9M | $803,000.00 |
| Operating income | -$3.8M | -$17.5M | -$18.0M | -$21.0M | -$16.5M | -$23.3M |
| Net income | -$3.7M | -$17.0M | -$18.8M | -$21.4M | -$16.0M | -$22.7M |
| Diluted EPS | — | -$0.90 | -$0.90 | -$10.22 | -$2.62 | -$1.29 |
| Operating cash flow | -$2.4M | -$9.6M | -$14.0M | -$19.0M | -$13.9M | -$18.6M |
| Free cash flow | -$2.5M | -$10.0M | -$14.5M | -$19.3M | -$14.5M | -$18.9M |
| Gross margin | 32.4% | 45.2% | 40.7% | 31.2% | 78.8% | 67.0% |
| Operating margin | -67.1% | -1336.6% | -1476.5% | -2966.0% | -690.7% | -1942.2% |
| Net margin | -66.1% | -1305.1% | -1541.3% | -3020.2% | -667.8% | -1893.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $468,000.00 | $773,000.00 | $603,000.00 | $381,000.00 | $316,000.00 | $137,000.00 | $365,000.00 | $398,000.00 |
| Gross profit | $344,000.00 | $682,000.00 | $529,000.00 | $275,000.00 | $146,000.00 | $125,000.00 | $257,000.00 | $264,000.00 |
| Operating income | -$3.5M | -$4.6M | -$4.3M | -$5.2M | -$5.4M | -$7.3M | -$5.4M | -$4.8M |
| Net income | -$3.4M | -$4.4M | -$4.1M | -$5.0M | -$5.0M | -$7.2M | -$5.4M | -$4.7M |
| Diluted EPS | -$1.83 | -$0.34 | $1.16 | -$0.34 | -$0.33 | -$0.39 | -$0.23 | -$0.19 |
| Operating cash flow | -$4.6M | -$2.8M | -$3.4M | -$4.7M | -$3.6M | -$5.1M | -$5.3M | -$4.4M |
| Free cash flow | -$4.8M | -$3.3M | -$3.4M | -$4.7M | -$3.8M | -$5.1M | -$5.3M | -$4.4M |
| Gross margin | 73.5% | 88.2% | 87.7% | 72.2% | 46.2% | 91.2% | 70.4% | 66.3% |
| Operating margin | -747.9% | -601.4% | -710.3% | -1359.8% | -1707.9% | -5335.8% | -1479.2% | -1199.7% |
| Net margin | -729.3% | -571.7% | -677.1% | -1315.2% | -1591.1% | -5270.8% | -1491.5% | -1189.9% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Hare Joshua· Chief Scientific Officer | Award | 600,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Locklear Lisa· Chief Financial Officer | Tax withholding | 22,505 | $0.73 | $16,408.40 | filing |
| 2026-07-01 | Agafonova Nataliya· Chief Medical Officer | Tax withholding | 22,505 | $0.73 | $16,408.40 | filing |
| 2026-07-01 | Willard Stephen H· Chief Executive Officer | Tax withholding | 18,046 | $0.73 | $13,157.34 | filing |
| 2026-07-01 | Blass Devin· CTO & SVP of CMC | Tax withholding | 15,808 | $0.73 | $11,525.61 | filing |
| 2026-07-01 | Lehr Paul T· General Counsel, Secretary | Tax withholding | 13,143 | $0.73 | $9,582.56 | filing |
| 2026-05-01 | Lehr Paul T· General Counsel, Secretary | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-05-01 | Willard Stephen H· Chief Executive Officer | Award | 500,000 | $0.00 | $0.00 | filing |
| 2026-05-01 | Blass Devin· CTO & SVP of CMC | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-05-01 | Agafonova Nataliya· Chief Medical Officer | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-05-01 | Locklear Lisa· Chief Financial Officer | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Agafonova Nataliya· Chief Medical Officer | Tax withholding | 13,145 | $1.12 | $14,722.40 | filing |
| 2026-04-01 | Locklear Lisa· Chief Financial Officer | Tax withholding | 13,145 | $1.12 | $14,722.40 | filing |
| 2026-04-01 | Blass Devin· CTO & SVP of CMC | Tax withholding | 8,633 | $1.12 | $9,668.96 | filing |
| 2026-04-01 | Lehr Paul T· General Counsel, Secretary | Tax withholding | 5,611 | $1.12 | $6,284.32 | filing |
| 2026-04-01 | Willard Stephen H· Chief Executive Officer | Tax withholding | 4,740 | $1.12 | $5,308.80 | filing |
| 2026-03-02 | Willard Stephen H· Chief Executive Officer | Tax withholding | 105,533 | $0.55 | $57,515.49 | filing |
| 2026-03-02 | Willard Stephen H· Chief Executive Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-03-02 | Willard Stephen H· Chief Executive Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Blass Devin· CTO & SVP of CMC | Tax withholding | 10,700 | $0.59 | $6,345.10 | filing |
| 2026-01-02 | Locklear Lisa· Chief Financial Officer | Tax withholding | 10,250 | $0.59 | $6,078.25 | filing |
| 2026-01-02 | Agafonova Nataliya· Chief Medical Officer | Tax withholding | 10,250 | $0.59 | $6,078.25 | filing |
| 2026-01-02 | Lehr Paul T· General Counsel, Secretary | Tax withholding | 6,952 | $0.59 | $4,122.54 | filing |
| 2026-01-02 | Powell James Nathaniel· Chief Executive Officer | Tax withholding | 2,464 | $0.59 | $1,461.15 | filing |
| 2025-10-01 | Locklear Lisa· Chief Financial Officer | Tax withholding | 11,883 | $0.74 | $8,821.94 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.